Medical technology for early cancer detection and treatment monitoring

Claim My Business View on Republic
Security Type
Crowd SAFE
Min Investment
Laredo, TX
Offering Date
May 06, 2022
Expected Close Date
September 24, 2022
Amount Raised
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

According to the International Agency for Research on Cancer (IARC), in 2020, the number of new registered cases surpassed 19.2 M globally, whereas over 9.9 M deaths were attributed to this disease [1]. Despite all the recent breakthroughs in cancer treatments, it is estimated that by 2040, the number of new registered cases and fatalities per year will increase to 30.2 M and 16.3 M, respectively [2, 3].  One of the main reasons cancer still has such a high mortality rate is due to the current lack of tests with the required sensitivity and specificity to aid in the early diagnosis of the disease.

Key Deal Facts

Delee has a patent pending technology that is already fully functional
Delee is running clinical studies for prostate and breast cancer
Our company has a multidisciplinary team of scientists and engineers
We are backed by Y Combinator, StartX, and Emles Venture Partners
Delee is going to start sales as a research use only device by Q4 of 2022
Delee has secured 11 LOIs worth a potential value of over $2.5M USD
The clinical market for CTCs has a TAM of $543B USD

Security Description

An equity crowdfunding specific version of a SAFE used by crowdfunding portal Republic. Upon conversion (if and when that happens), investors may receive special shares with limited rights that do not show up on a company’s cap table. The issuer may roll over and not convert shares at the next financing round causing investors to lose out on some upside.

Research Reports

No reports have been submitted

Become a Reporter